(Total Views: 281)
Posted On: 09/20/2018 11:15:20 PM
Post# of 2022
Things to consider as Q4 comes to a close in 10 days. IMO, the real wildcard will be the new lab in Oregon. I believe revenues should be much higher than q3. Note Mass. did have revenues from medical.
From the date of acquisition on January 1, 2018 to June 30, 2018 C3 Labs generated total revenues of $75,835
From the date of acquisition on May 2, 2018 to June 30, 2018 Keystone generated total revenues of $73,284.
From the date of acquisition on April 29, 2018 to June 30, 2018 EVIO Humboldt generated total revenues of $7,560.
. In addition, the Company’s acquisition of Viridis, a lab located in Massachusetts attributed $32,400 of revenue in the three months ending June 30, 2018 versus no revenues for the three months ending March 31, 2017.
As of June 30, 2018 and September 30, 2017, the Company had a note receivable totaling $1,300,000 and $1,300,000 due from a single entity.(Lab loan for Co. Lab coming due Sept. 30,2018). Amount payable $1,404,000
From the date of acquisition on January 1, 2018 to June 30, 2018 C3 Labs generated total revenues of $75,835
From the date of acquisition on May 2, 2018 to June 30, 2018 Keystone generated total revenues of $73,284.
From the date of acquisition on April 29, 2018 to June 30, 2018 EVIO Humboldt generated total revenues of $7,560.
. In addition, the Company’s acquisition of Viridis, a lab located in Massachusetts attributed $32,400 of revenue in the three months ending June 30, 2018 versus no revenues for the three months ending March 31, 2017.
As of June 30, 2018 and September 30, 2017, the Company had a note receivable totaling $1,300,000 and $1,300,000 due from a single entity.(Lab loan for Co. Lab coming due Sept. 30,2018). Amount payable $1,404,000
(0)
(0)
